May 6, 2014 (Shareholders Foundation) - An investigation on behalf of investors of ABIOMED, Inc. (NASDAQ:ABMD) shares over potential securities laws violations by ABIOMED, Inc. and certain of its directors and officers in connection certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of ABIOMED, Inc. (NASDAQ:ABMD) concerning whether a series of statements by ABIOMED, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

ABIOMED, Inc. reported that its Total Revenue rose from $101.15 million for the 12 months period that ended on March 31, 2014 to $183.64 million for the 12 months period that ended on March 31, 2014.

Shares of ABIOMED, Inc. (NASDAQ:ABMD) grew from $12.25 per share in early 2013 to as high as $29.98 per share in March 2014.

Then on May 1, 2014, ABIOMED, Inc. announced its fourth quarter 2014 results. Among other things, ABIOMED, Inc. said that on April 25, 2014, ABIOMED received a subpoena from theBoston regional office of the United States Department of Health and Human Services, Office of Inspector General requesting materials relevant to the Company's reimbursement of expenses and remuneration to healthcare providers during the period ofJuly 2012 December 2012. Shares of ABIOMED, Inc. declined to as low as $21.61 per share on May 1, 2014.

On May 5, 2014, NASDAQ:ABMD shares closed at $22.23 per share.